Bioanalytical Community

Risk Factors, Hyaluronidase Expression, and Clinical Immunogenicity of Recombinant Human Hyaluronidase PH20, an Enzyme Enabling Subcutaneous Drug Administration - The AAPS Journal SpringerLink remove preview Risk Factors, Hyaluronidase Expression, and Clinical Immunogenicity of Recombinant Human Hyaluronidase PH20, an Enzyme Enabling Subcutaneous Drug Administration - The AAPS Journal Multiple FDA-approved and clinical-development stage therapeutics include recombinant human hyaluronidase PH20 (rHuPH20) to facilitate subcutaneous administration. As rHuPH20-reactive antibodies potentially interact with endogenous PH20, we investigated rHuPH20 immunogenicity risk through hyaluronidase tissue expression, predicted B cell epitopes, CD4+ T cell stimulation indices and related these to observed clinical immunogenicity profiles from 18 clinical studies. View this on SpringerLink >

To view the full article through your AAPS membership:

Go to https://www.aaps.org/education-and-research/journals/the-aaps-journal 

Enter your AAPS credentials

Click "Member Access to Journals"

Click on the The AAPS Journal cover.

Copy and paste the url into the "Search" box, and click search

The full article should appear.

 

Follow The AAPS Journal via Twitter and LinkedIn.

------------------------------
Ho-Leung Fung Ph.D., FAAPS
Editor-in-Chief
University at Buffalo
Sarasota FL
[email protected]

Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
------------------------------